Clinical Trials Logo

RRMM clinical trials

View clinical trials related to RRMM.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03778346 Recruiting - RRMM Clinical Trials

Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells

Start date: November 15, 2018
Phase: Phase 1
Study type: Interventional

According to the high expression of tumor cell-associated antigen CD138, integrin β7, CS1, CD38 and BCMA in patients with refractory/recurrent multiple myeloma, the fourth generation of CAR-T cells(simultaneously expressing IL7 and CCL19) with 10 different dual target combinations are used to minimize the tumor burden in the patient individually and precisely and improve the immunosuppressive microenvironment of the tumor , thereby effectively treating refractory/recurrent multiple myeloma .